HOME  |  RESOURCES

RESOURCES

 stratifies Hormone Receptor positive breast cancer patients as ‘low or high’ risk for cancer recurrence and aids in personalized treatment planning.

stratifies Hormone Receptor positive breast cancer patients as ‘low or high’ risk for cancer recurrence and aids in personalized treatment planning.

FAQ'S

1). How can I order CanAssist-Breast?
2). Who can use CanAssist-Breast?
3). How long will the report take to arrive?
4). How will the CanAssist-Breast test results help me?
5). What kind of samples are required to perform CanAssist-Breast?
6). Where is CanAssist-Breast test performed?

PUBLICATIONS

  • Ramkumar C, Prakash C, Madhav L, Kumar A, Basavaraj C, et al. (2017) Assessment of Ki67 As a Prognostic Marker in Hormone Receptor Positive Breast Cancer: A Retrospective Study on An Indian Cohort. J Mol Biomark Diagn 8: 336. doi: 10.4172/2155-9929.1000336
 
  • Clinical development and validation of a morphometric IHC test to predict risk of recurrence in patients with early-stage ER/PR+ Invasive Ductal Carcinoma of Breast (manuscript under preparation).
 
  • Analytical Validation of the lmmunohistochemistry-based CanAssist- Breast Prognostic Test for Prediction of Risk of Recurrence in Hormone Receptor- Positive Breast Cancer (manuscript under review).

INVITED TALKS

  • Charusheila Ramkumar, CanAssist-Breast: Innovative test for prediction of risk of recurrence, Beyond ER, PR and Her2. International Cancer Congress, 9-10th July 2016, Nagpur.

  • Bakre MM, CanAssist-Breast: Innovative test for prediction of risk of recurrence, Beyond ER, PR and Her2. ABSICON 2016, 1-3rd July 2016, Bangalore.

  • Bakre MM, Development and validation of IHC based test for prediction of risk of recurrence for breast cancer patients: Beyond ER, PR and Her2. Advanced Diagnostics, 27-28th May 2016, Bangalore.

  • Bakre MM, Development and validation of IHC based test for prediction of risk of recurrence for breast cancer patients: Beyond ER, PR and Her2. Indian Association of Cancer Research, 10th April 2016, New Delhi.

  • Charusheila Ramkumar, “Stem Cell therapeutics in Cancer”, Symposium on Stem Cell therapeutics, Oxford College, Bangalore, 2016.

  • Charusheila Ramkumar, Development of a broad-based test to predict risk of recurrence in patients with Hormone Receptor positive, early-stage Breast Cancer” , Poster presentation, MOSCON 2016, Pune.

  • Charusheila Ramkumar, “OncoStem Diagnostics, Redefining Cancer treatment”, BioKorea 2016.

  • Charusheila Ramkumar, “A novel diagnostic test to predict risk of recurrence in Breast Cancer”, Scientific presentation at Global Cancer Summit, Bangalore, 2015.

  • Bakre MM, Development and Validation of Indigenous ‘risk of recurrence’ stratification test in breast cancer. The international symposium on Molecular Oncology and Translational Cancer Research - The 3Bs - Bench, Bedside & Business, 1St November 2015, Delhi.

  • Bakre MM, Development of IHC based test for prediction of risk of recurrence for breast cancer patients. Biomarkers-2015, Toronto, Canada.

  • BakreMM, Development of IHC based test for prediction of risk of recurrence for breast cancer patients. Indian Association of Cancer Research 2015, Jaipur.

  • Bakre MM, Trends in Biomarker discovery in cancer: The devil is in molecular pathways. Invited Speaker, Emerging Technologies Session. Indian Cancer Congress, November 2013, New Delhi.

  • Bakre MM, Development of IHC based test for prediction of risk of recurrence for breast cancer patients. Plenary Talk. Indian Cancer Congress, November 2013, New Delhi.

  • Bakre MM, Invited panellist at Start-Up festival in Bangalore, Discussion: Challenges in Life Science Start-Ups: Founder’s perspective, March 2013.

  • Bakre MM, Invited panellist at TiE Bangalore, Discussion: How to find and close early stage investors, January 2013, Bangalore.

  • Bakre MM, Towards developing intelligent cancer diagnostics, Indian Statistical Institute, April 2012, Bangalore.